All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Heptares Therapeutics Ltd. said the starting gun has been fired on a $190 million-plus-royalties deal, after Shire plc decided to take up its option on an A2A antagonist discovered by Heptares.